ABRA INVEST advises HEMOSOLVE on its strategic development

22/03/2013
Diego Gutiérrez
ABRA INVEST advises HEMOSOLVE on its strategic development

ABRA INVEST has collaborated with HEMOSOLVE (exploitation of "sclerosing microfoam" for the treatment of haemorrhoids) through the design of a plan to develop its own clinics and agreements with other prestigious institutions.

History of microfoam sclerosants

In 1993 the Cabrera family invented the sclerosing microfoam. Since then it has been used to treat varicose veins effectively in more than 25,000 patients. As well as being treated in Cabrera's own 5 clinics, the treatment is used under licence by prestigious institutions such as the Clínica Universitaria de Navarra and Sanitas hospitals. Following the success of the microfoam treatment for varicose veins, the inventors have developed microfoam for haemorrhoids.

KEY POINTS:

1. Large size of affected population:

Symptomatic haemorrhoids affect at least 50% of the population at some point in their lives, with around 5% of the population suffering from them at any one time.
2. Advantages over surgery and others:
  • Outpatient treatment: no need for anaesthesia or surgery.
  • No specific post-treatment care and the patient can continue with normal life.
  • HEMOSOLVE can cure any type of haemorrhoid. Surgery only for the most acute ones.
  • Painless and easily repeatable procedure: The discomfort is similar to a blood draw.

3. Advantageous competitive position:

  • The technology is patented and IIDF has authorisation for use in Spain.
  • The treatment has been tested in more than 150 patients during 2011 and 2012 demonstrating its efficacy. The Granada Clinic is active.
  • Agreements with other institutions underway: agreement with Clínicas Cabrera to offer the treatment, agreement with Médico Digestivo to open a clinic in Madrid, etc.

The team composed of technical staff and professionals with business experience in the healthcare world is well prepared to develop the established business plan.

Diego Gutiérrez Zarza

Baker Tilly GDA

Lastest news

State of technology M&A in Spain | Analysis August 2025

El mes de agosto, tradicionalmente más pausado en cuanto a transacciones corporativas, ha sorprendido en 2025 con una intensa actividad en el ámbito tecnológico en España. Se registraron operaciones de gran calado en segmentos como marketplaces digitales,...

Baker Tilly advises BSG on its acquisition of Copermática

The advisors for the sale and purchase of technology companies at Baker Tilly Tech M&A have advised Business Software Group (BSG) on its recent acquisition of Copermática, a company specialising in management software for professional firms and consultancies. With...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42